Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.75 |
| ▸ | QPCT | Q16769 | 12/20 | 0.58 |
| ▸ | QPCTL | Q9NXS2 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28292532 | 0.87 | MMP12 (0.60) | MMP12QPCTQPCTLNPC1RAB9A | |
| SCHEMBL225932 | 0.86 | MMP12 (1.00) | MMP12QPCTQPCTLNPC1RAB9A | |
| SCHEMBL29424791 | 0.86 | MMP12 (1.00) | MMP12QPCTQPCTLNPC1RAB9A | |
| SCHEMBL28294180 | 0.86 | MMP12 (0.69) | MMP12QPCTQPCTLALDH1A1 | |
| SCHEMBL8634290 | 0.84 | QPCT (0.68) | MMP12QPCTQPCTLNPC1RAB9A | |
| SCHEMBL2093316 | 0.83 | MMP12 (0.56) | MMP12QPCTQPCTLNPC1RAB9A | |
| SCHEMBL6869415 | 0.80 | ACVR1 (0.63) | MMP12NPC1RAB9AKDM4EPDPK1 | |
| SCHEMBL2462345 | 0.79 | QPCT (0.68) | QPCTQPCTLNPC1RAB9AKDM4E | |
| Benzimidazole SCHEMBL15413095 | 0.79 | MMP12 (0.84) | MMP12QPCTQPCTLNPC1RAB9A | |
| SCHEMBL38665709 | 0.77 | QPCT (0.66) | MMP12QPCTQPCTLNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106866543-B | A method of benzimidazole compound is catalyzed and synthesized under microwave radiation in water phase | 福建医科大学 | 2019-05-14 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | MMP12 3540/4885QPCT 731/4885QPCTL 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.